✦ LIBER ✦

P1111 ANRS HC15 NRFI: LONG-TERM MAINTENANCE THERAPY WITH A COMBINATION OF RIBAVIRIN AND PEGYLATED INTERFERON IN CHRONIC HEPATITIS C. RESULTS OF A MULTICENTER RANDOMIZED CONTROLLED TRIAL

✍ Scribed by Guyader, D.; Bellissant, E.; Asselah, T.; Bronowicki, J.P.; Abergel, A.; Lasser, L.; Tran, A.; Bourlière, M.; Samuel, D.; Wartelle, C.; Beaugrand, M.; Trépo, C.; Riachi, G.; Attali, P.; D'alteroche, L.; Gournay, J.; Vinel, J.P.; Schnee, M.; Henrion, J.; Doffoel, M.; Hillon, P.; Adler, M.; Turlin, B.; Renault, A.; Bedossa, P.; Calès, P.; Delwaide, J.

Book ID: 123325496
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 79 KB
Volume: 60
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(14)61271-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P.247 Prediction of treatment outcome in

P.247 Prediction of treatment outcome in genotype 4 chronic hepatitis C patients during combined pegylated interferon alpha-2a and ribavirin therapy (ANRS 1211 trial)

✍ G. Esmat; H. ElMakhzangy; S. Males; R.R. Gad; C. Rekacewicz; S.A. Ismail; M. Abd 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 143 KB

A randomized trial of 48 versus 24 weeks

A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C

✍ Pham Thi Thu Thuy; Chalermrat Bunchorntavakul; Ho Tan Dat; K. Rajender Reddy 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 852 KB

An open-label randomized controlled stud

An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin

✍ C. Kondo; M. Atsukawa; A. Tsubota; N. Itokawa; T. Fukuda; Y. Matsushita; H. Kido 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB

The efficacy and safety of pegylated int

The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies – A multicenter prospective trial

✍ Jee-Fu Huang; Ming-Lung Yu; Chung-Feng Huang; Chang-Fu Chiu; Chia-Yen Dai; Ching 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 806 KB

A multicenter survey of re-treatment wit

A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan

✍ Oze, Tsugiko; Hiramatsu, Naoki; Mita, Eiji; Akuta, Norio; Sakamoto, Naoya; Nagan 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB

Randomized controlled trial of pegylated

Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6

✍ Khoa D. Lam; Huy N. Trinh; Son T. Do; Thuan T. Nguyen; Ruel T. Garcia; Tuan Nguy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB 👁 2 views

Hepatitis C virus (HCV) genotype is an important criteria in determining duration of therapy and predictor of sustained virologic response (SVR) to pegylated interferon (PEG IFN) and ribavirin (RBV) therapy. Optimal duration of therapy for patients with HCV genotype 6 is not known. We conducted a mu